Walter Roberts1, Emily L R Harrison2, Sherry A McKee2. 1. Yale School of Medicine, Department of Psychiatry, Yale University School of Medicine, Church St. South, Suite 109, New Haven, CT, 06519, USA. walter.roberts@yale.edu. 2. Yale School of Medicine, Department of Psychiatry, Yale University School of Medicine, Church St. South, Suite 109, New Haven, CT, 06519, USA.
Abstract
RATIONALE: Clinical trials and human laboratory studies have established that varenicline can reduce rates of alcohol use among heavy drinkers. Less is known about the mechanisms by which varenicline has this effect on drinking behavior. Reactivity to alcohol cues is often cited as the primary cause of relapse among those being treated for alcohol use disorder, and several front-line treatments for alcohol use disorder work, at least in part, by minimizing cue-induced alcohol craving. OBJECTIVE: The current double-blind, placebo-controlled human laboratory study tested the effects of varenicline on alcohol cue reactivity in a group of heavy-drinking adult smokers and nonsmokers. METHODS: As part of a larger series of sequential human laboratory experiments testing the effects of varenicline on drinking outcomes, participants were assigned (between-participant) to receive either active varenicline (2 mg/day) or placebo. Following a titration period, participants (n = 77) attended a laboratory session during which they were exposed to alcohol and neutral cues using a standard cue reactivity paradigm. RESULTS: Alcohol cue exposure increased craving for alcohol in both medication groups. However, participants receiving varenicline showed a smaller increase in alcohol craving compared to participants receiving placebo. The medication effect did not differ between smokers and nonsmokers. Among smokers, alcohol cue exposure also increased tobacco craving. Varenicline did not attenuate this effect. CONCLUSIONS: Results support the use of varenicline for reducing alcohol use in heavy drinkers and identify a potential mechanism by which varenicline reduces drinking. Varenicline continues to show promise as a pharmacological treatment for alcohol use disorder.
RCT Entities:
RATIONALE: Clinical trials and human laboratory studies have established that varenicline can reduce rates of alcohol use among heavy drinkers. Less is known about the mechanisms by which varenicline has this effect on drinking behavior. Reactivity to alcohol cues is often cited as the primary cause of relapse among those being treated for alcohol use disorder, and several front-line treatments for alcohol use disorder work, at least in part, by minimizing cue-induced alcohol craving. OBJECTIVE: The current double-blind, placebo-controlled human laboratory study tested the effects of varenicline on alcohol cue reactivity in a group of heavy-drinking adult smokers and nonsmokers. METHODS: As part of a larger series of sequential human laboratory experiments testing the effects of varenicline on drinking outcomes, participants were assigned (between-participant) to receive either active varenicline (2 mg/day) or placebo. Following a titration period, participants (n = 77) attended a laboratory session during which they were exposed to alcohol and neutral cues using a standard cue reactivity paradigm. RESULTS:Alcohol cue exposure increased craving for alcohol in both medication groups. However, participants receiving varenicline showed a smaller increase in alcohol craving compared to participants receiving placebo. The medication effect did not differ between smokers and nonsmokers. Among smokers, alcohol cue exposure also increased tobacco craving. Varenicline did not attenuate this effect. CONCLUSIONS: Results support the use of varenicline for reducing alcohol use in heavy drinkers and identify a potential mechanism by which varenicline reduces drinking. Varenicline continues to show promise as a pharmacological treatment for alcohol use disorder.
Entities:
Keywords:
Alcohol; Alcohol craving; Cue reactivity; Human laboratory; Smokers; Varenicline
Authors: Andrea de Bejczy; Elin Löf; Lisa Walther; Joar Guterstam; Anders Hammarberg; Gulber Asanovska; Johan Franck; Anders Isaksson; Bo Söderpalm Journal: Alcohol Clin Exp Res Date: 2015-09-28 Impact factor: 3.455
Authors: Robert Miranda; Stephanie S O'Malley; Hayley Treloar Padovano; Ran Wu; Daniel E Falk; Megan L Ryan; Joanne B Fertig; Thomas H Chun; Srinivas B Muvvala; Raye Z Litten Journal: Alcohol Clin Exp Res Date: 2020-05-25 Impact factor: 3.455
Authors: Ralph L Elkins; Todd L Richards; Robert Nielsen; Richard Repass; Henriettae Stahlbrandt; Hunter G Hoffman Journal: Front Behav Neurosci Date: 2017-09-28 Impact factor: 3.558
Authors: Erica N Grodin; Elizabeth M Burnette; ReJoyce Green; Aaron C Lim; Karen Miotto; Lara A Ray Journal: Drug Alcohol Depend Date: 2021-06-23 Impact factor: 4.852